Compile Data Set for Download or QSAR
Report error Found 90 Enz. Inhib. hit(s) with all data for entry = 10811
Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570555([4-(propan-2-yloxy)phenyl]methyl N-[(7S,8aS)-octah...)
Affinity DataKi:  0.0160nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570569(US11440884, Example 30)
Affinity DataKi:  0.0320nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570568(US11440884, Example 29)
Affinity DataKi:  0.0630nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570567(US11440884, Example 28)
Affinity DataKi:  0.0790nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570628(US11440884, Example 77)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570602(US11440884, Example 54)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570603(US11440884, Example 55)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570616(US11440884, Example 67)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570619(US11440884, Example 70)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570621(US11440884, Example 71)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570622(US11440884, Example 72)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570627(US11440884, Example 76)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570574(US11440884, Example 35)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570571(US11440884, Example 32)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570526([4-(propan-2-yloxy)phenyl]methyl N-[(3S,4R)-3-fluo...)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570525( [4-(propan-2-yloxy)phenyl]methyl N-[(3R,4S)-3-flu...)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570524([4-(propan-2-yloxy)phenyl]methyl N-[(4-fluoropheny...)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570517([4-(propan-2-yloxy)phenyl]methyl N-[(4-fluoropheny...)
Affinity DataKi:  0.100nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570516(US11440884, Example 2)
Affinity DataKi:  0.126nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570545(US11440884, Example 13)
Affinity DataKi:  0.126nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570587(US11440884, Example 39)
Affinity DataKi:  0.158nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570566(US11440884, Example 27)
Affinity DataKi:  0.158nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570515(US11440884, Example 1)
Affinity DataKi:  0.200nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570565(US11440884, Example 25)
Affinity DataKi:  0.200nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570544(US11440884, Example 12)
Affinity DataKi:  0.251nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570543(US11440884, Example 11)
Affinity DataKi:  0.251nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570530([4-(2-methylpropoxy)phenyl]methyl N-[(3S,4R)-3-flu...)
Affinity DataKi:  0.251nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570529([4-(2-methylpropoxy)phenyl]methyl N-[(3R,4S)-3-flu...)
Affinity DataKi:  0.251nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570528([4-(2-methylpropoxy)phenyl]methyl N-[(4-fluorophen...)
Affinity DataKi:  0.251nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570527([4-(2-methylpropoxy)phenyl]methyl N-[(4-fluorophen...)
Affinity DataKi:  0.251nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570592(US11440884, Example 44)
Affinity DataKi:  0.398nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570623(US11440884, Example 73)
Affinity DataKi:  0.398nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570586(US11440884, Example 38)
Affinity DataKi:  0.501nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570564(US11440884, Example 26)
Affinity DataKi:  0.501nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570549(US11440884, Example 15)
Affinity DataKi:  0.501nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570624(US11440884, Example 74)
Affinity DataKi:  0.794nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570575(US11440884, Example 36)
Affinity DataKi:  1nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570588(US11440884, Example 40)
Affinity DataKi:  1.26nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570576(US11440884, Example 37)
Affinity DataKi:  1.26nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570633(US11440884, Example 81)
Affinity DataKi:  2nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570593(US11440884, Example 45)
Affinity DataKi:  2.51nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570560(US11440884, Example 21)
Affinity DataKi:  2.51nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570589(US11440884, Example 41)
Affinity DataKi:  2.51nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570591(US11440884, Example 43)
Affinity DataKi:  3.16nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570612(US11440884, Example 63)
Affinity DataKi:  3.98nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570615(US11440884, Example 66)
Affinity DataKi:  3.98nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570631(US11440884, Example 79)
Affinity DataKi:  3.98nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570558(US11440884, Example 19)
Affinity DataKi:  5.01nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570559(US11440884, Example 20)
Affinity DataKi:  6.31nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM570561(US11440884, Example 22)
Affinity DataKi:  6.31nMAssay Description:R-SAT's were generally performed with 50 ng/well of receptor and 20 ng/well of β-galactosidase plasmid DNA. All receptor constructs used wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 90 total ) | Next | Last >>
Jump to: